Jiang Shan, Deng Xinzhou, Luo Ming, Zhou Le, Chai Jingjing, Tian Chao, Yan Yutao, Luo Zhiguo
Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Hubei Key Laboratory of Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Front Oncol. 2023 Sep 6;13:1207081. doi: 10.3389/fonc.2023.1207081. eCollection 2023.
2',5'-oligoadenylate synthetase 1 (OAS1), has been reported as a tumor driver gene in breast carcinoma and pancreatic carcinoma. However, the role of OAS1 in most tumors has not been reported.
The original data of 35 tumor types were down load from the TCGA (The Cancer Genome Atlas) database and Human Protein Atlas (HPA) database. TIMER2, Kmplot, UALCAN, and TISIDB tools were used to investigate the expression and function of OAS1, and the role of OAS1 in prognosis, diagnostic value, and immune characteristics of pan-cancer. LUAD and PRAD cell lines, A549, H1975, PC-3 and C4-2 were utilized to perform cell function tests.
OAS1 expression was up-regulated in 12 tumor types and down-regulated in 2 tumor types. High OAS1 expression was correlated with poor prognosis in 6 tumor types, while high OAS1 expression was correlated with good prognosis in 2 tumor types. OAS1 was correlated with molecular subtypes in 8 tumor types and immune subtypes in 12 tumor types. OAS1 was positively associated with the expression of numerous immune checkpoint genes and tumor mutational burden (TMB). OAS1 had potential diagnostic value in 15 tumor types. Silence of OAS1 significantly inhibited the cell proliferation ability, and promoted G2/M cell cycle arrest of LUAD and PRAD cells. Meanwhile, silence of OAS1 enhanced cisplatin-induced apoptosis of LUAD and PRAD cells, but weakened cell migration.
This pan-cancer study suggests that OAS1can be used as a molecular biomarker for prognosis in pan-cancer and may play an important role in tumor immune response.
2',5'-寡腺苷酸合成酶1（OAS1）已被报道为乳腺癌和胰腺癌中的肿瘤驱动基因。然而，OAS1在大多数肿瘤中的作用尚未见报道。
从癌症基因组图谱（TCGA）数据库和人类蛋白质图谱（HPA）数据库下载35种肿瘤类型的原始数据。使用TIMER2、Kmplot、UALCAN和TISIDB工具研究OAS1的表达和功能，以及OAS1在泛癌预后、诊断价值和免疫特征中的作用。利用肺腺癌（LUAD）和前列腺癌（PRAD）细胞系A549、H1975、PC-3和C4-2进行细胞功能测试。
OAS1表达在12种肿瘤类型中上调，在2种肿瘤类型中下调。OAS1高表达与6种肿瘤类型的不良预后相关，而OAS1高表达与2种肿瘤类型的良好预后相关。OAS1与8种肿瘤类型的分子亚型和12种肿瘤类型的免疫亚型相关。OAS1与多种免疫检查点基因的表达和肿瘤突变负荷（TMB）呈正相关。OAS1在15种肿瘤类型中具有潜在的诊断价值。沉默OAS1可显著抑制LUAD和PRAD细胞的增殖能力，并促进其G2/M期细胞周期阻滞。同时，沉默OAS1增强了顺铂诱导的LUAD和PRAD细胞凋亡，但减弱了细胞迁移。
这项泛癌研究表明，OAS1可作为泛癌预后的分子生物标志物，并可能在肿瘤免疫反应中发挥重要作用。
